6BG.F Lytix Biopharma AS

Healthcare Biotechnology Frankfurt Exchange
0.8880 EUR
Close of Nov 11, 2026
0.6600 1.02
Market cap
EUR 68.3M
P/E
-
P/B
6.78x
ROE
-121.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 6BG.F undervalued?

Graham number

The Graham number of Lytix Biopharma AS cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Lytix Biopharma AS fundamental analysis

No fundamental analysis for Lytix Biopharma AS yet.

Lytix Biopharma AS stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Lytix Biopharma AS

Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is ruxotemitide, an oncolytic molecule that is developed for intratumoral injections, which is in Phase III clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma; and NeoLIPA Phase II study in combination with pembrolizumab. The company also offers LTX-401, an oncolytic molecule i…

Full company profile